physiologically based pharmacokinetics (PBPK);
pharmacokinetics;
neonates;
volume of distribution;
allometric scaling;
developmental pharmacology;
HUMAN SERUM-ALBUMIN;
SINGLE-DOSE PHARMACOKINETICS;
POPULATION PHARMACOKINETICS;
PROTEIN-BINDING;
PRETERM INFANTS;
CEFTAZIDIME PHARMACOKINETICS;
CLINICAL PHARMACOKINETICS;
MORPHINE PHARMACOKINETICS;
IMIPENEM-CILASTATIN;
HEALTHY-VOLUNTEERS;
D O I:
10.3390/pharmaceutics15092348
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
The volume of distribution at steady state (Vss) in neonates is still often estimated through isometric scaling from adult values, disregarding developmental changes beyond body weight. This study aimed to compare the accuracy of two physiologically based pharmacokinetic (PBPK) Vss prediction methods in neonates (Poulin & Theil with Berezhkovskiy correction (P & T+) and Rodgers & Rowland (R & R)) with isometrical scaling. PBPK models were developed for 24 drugs using in-vitro and in-silico data. Simulations were done in Simcyp (V22) using predefined populations. Clinical data from 86 studies in neonates (including preterms) were used for comparison, and accuracy was assessed using (absolute) average fold errors ((A)AFEs). Isometric scaling resulted in underestimated Vss values in neonates (AFE: 0.61), and both PBPK methods reduced the magnitude of underprediction (AFE: 0.82-0.83). The P & T+ method demonstrated superior overall accuracy compared to isometric scaling (AAFE of 1.68 and 1.77, respectively), while the R & R method exhibited lower overall accuracy (AAFE: 2.03). Drug characteristics (LogP and ionization type) and inclusion of preterm neonates did not significantly impact the magnitude of error associated with isometric scaling or PBPK modeling. These results highlight both the limitations and the applicability of PBPK methods for the prediction of Vss in the absence of clinical data.
机构:
AstraZeneca, Sci & Data Analyt Div, Res & Dev, Kita Ku, KK 3-1,Ofuka Cho, Osaka 5300011, JapanAstraZeneca, Sci & Data Analyt Div, Res & Dev, Kita Ku, KK 3-1,Ofuka Cho, Osaka 5300011, Japan
Higashimori, Mitsuo
Ishikawa, Kensuke
论文数: 0引用数: 0
h-index: 0
机构:
AstraZeneca, Sci & Data Analyt Div, Res & Dev, Kita Ku, KK 3-1,Ofuka Cho, Osaka 5300011, JapanAstraZeneca, Sci & Data Analyt Div, Res & Dev, Kita Ku, KK 3-1,Ofuka Cho, Osaka 5300011, Japan
Ishikawa, Kensuke
Gillen, Michael
论文数: 0引用数: 0
h-index: 0
机构:
AstraZeneca LP, Clin Pharmacol & Safety Sci, Res & Dev, 1 MedImmune Way, Gaithersburg, MD 20878 USAAstraZeneca, Sci & Data Analyt Div, Res & Dev, Kita Ku, KK 3-1,Ofuka Cho, Osaka 5300011, Japan
Gillen, Michael
Zhou, Diansong
论文数: 0引用数: 0
h-index: 0
机构:
AstraZeneca Pharmaceut LP, Clin Pharmacol & Safety Sci, Res & Dev, 35 Gatehouse Dr, Waltham, MA 02451 USAAstraZeneca, Sci & Data Analyt Div, Res & Dev, Kita Ku, KK 3-1,Ofuka Cho, Osaka 5300011, Japan
机构:
Simcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, EnglandSimcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, England
Chetty, Manoranjenni
Johnson, Trevor N.
论文数: 0引用数: 0
h-index: 0
机构:
Simcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, EnglandSimcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, England
Johnson, Trevor N.
Polak, Sebastian
论文数: 0引用数: 0
h-index: 0
机构:
Simcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, England
Jagiellonian Univ, Med Coll, Fac Pharm,Dept Social Pharm, Unit Phannacoepidemiol & Pharmacoecon, Med 9 Str, PL-30688 Krakow, PolandSimcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, England
Polak, Sebastian
Salem, Farzaneh
论文数: 0引用数: 0
h-index: 0
机构:
Simcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, EnglandSimcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, England
Salem, Farzaneh
Doki, Kosuke
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tsukuba, Fac Med, Dept Pharmaceut Sci, Ibaraki, Japan
Univ Manchester, Ctr Appl Phannacokinet Res CAPKR, Manchester, Lancs, EnglandSimcyp Ltd, Blades Enterprise Ctr, John St, Sheffield, S Yorkshire, England